On May 8, 2024 Celaid Therapeutics reported that it has raised an additional 460 million yen in its Series A extension round (Press release, Celaid Therapeutics, MAY 8, 2024, View Source [SID1234649811]). This round was led by The University of Tokyo Edge Capital Partners (UTEC) and OSAKA University Venture Capital (OUVC) with participation from Techno Science and Joyo Capital Partners. This brings Celaid’s total raise to approximately 1.2 billion yen which includes existing Series A funding of 500 million yen and the recent 200 million yen from the NEDO Deep Tech Startup grant.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celaid will apply the funding to advancing CMC process development in its lead pipeline asset for non-malignant hematologic disease in preparation for IND submission in the US. In parallel, Celaid will continue collaborations with partners exploring applications of its technology to HSC gene therapies and allogeneic immune cell therapies which include those utilizing iPSC-derived products.

"We were able to secure the necessary funds for future research and development in our Series A funding round thanks to new participating investors’ confidence in Celaid’s HSC-based platform and pipeline," said Nobuyuki Arakawa, President and Chief Executive Officer of Celaid.
"We are committed to delivering our unique HSC products to patients around the world as soon as possible."